CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) announced today that it has signed a three-year purchase agreement with the Swiss Red Cross Blood Service, with terms that anticipate deployment of the INTERCEPT Blood System for platelets in eleven of its thirteen blood centers. The Swiss Red Cross has oversight responsibility for blood centers supporting all Swiss cantons. The INTERCEPT Blood System for platelets, developed and marketed by Cerus, protects patients from platelet transfusions contaminated with bacteria and infectious disease by inactivating pathogens in donated blood. An estimated 31,000 platelet doses were prepared and transfused in Switzerland in 2009.
